The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced central ...

A specialty pharmacy company agreed to a $1.67 million settlement that it gave inventory management systems to retina ...

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding ...

Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema ...

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Pravin U. Dugel, MD, Ocular's Executive Chairman, President and CEO, will provide an update regarding the enrollment status ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ...